​
​

Petros Pharmaceuticals Stock (NASDAQ:PTPI)

RevenueOwnershipFinancialsChart
Petros Pharmaceuticals by TradingView

Previous Close

$0.35

52W Range

$0.28 - $2.27

50D Avg

$0.38

200D Avg

$0.90

Market Cap

$3.50M

Avg Vol (3M)

$325.09K

Beta

2.30

Div Yield

-

PTPI Company Profile

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

21

IPO Date

Dec 02, 2020

Website

PTPI Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Medical Devices$3.54M--
Medical Device Sales-$3.26M$3.21M
Prescription Medication Sales--$4.61M

Fiscal year ends in Dec 23 | Currency in USD

PTPI Financial Summary

Dec 23Dec 22Dec 21
Revenue$5.82B$5.99M$7.81M
Operating Income$-13.62B$-15.85M$-18.05M
Net Income$-13.81B$-27.04M$-9.36M
EBITDA$-5.42B$-6.84M$-11.17M
Basic EPS$-6.35$-13.06$-8.59
Diluted EPS$-6.35$-13.06$-8.59

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
SNOASonoma Pharmaceuticals, Inc.
AKANAkanda Corp.
EVOKEvoke Pharma, Inc.
TKNOAlpha Teknova, Inc.
SBFMSunshine Biopharma, Inc.
LFCRLifecore Biomedical, Inc.
GHSIGuardion Health Sciences, Inc.
ALIMAlimera Sciences, Inc.
SHPHShuttle Pharmaceuticals Holdings, Inc.
CPIXCumberland Pharmaceuticals Inc.
ADMPAdamis Pharmaceuticals Corporation
LSDILucy Scientific Discovery Inc.
PRFXPainReform Ltd.
AGRXAgile Therapeutics, Inc.
SXTCChina SXT Pharmaceuticals, Inc.